The Consortium for Improving Survival of Lymphoma (CISL): recent achievements and future perspective

Suh, Cheolwon; Park, Byeong-Bae; Kim, Won Seog

doi:10.5045/br.2017.52.1.3

Cited by 2 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By the end of 2017, the CISL has published the results of 36 retrospective studies to investigate the clinical and pathological features of Korean-specific lymphoma subtypes and evaluate the outcomes of new therapeutic modalities. Moreover, they also have performed more than 35 prospective clinical trials and reported the results of 20 prospective trials for DLBCL, MZL, ENKTL, and other subtypes [23]. Figure 4 presents the prospective chronological flow of prospective CISL trials.…”

Section: Survival Changes Based On Time In Major Subtypesmentioning

confidence: 99%

Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial

Yoo

Lee²,

Suh

et al. 2018

Int J Hematol

Self Cite

View full text Add to dashboard Cite

Lymphomas are a heterogeneous group of disease entities with well-defined clinical, morphological, immunophenotypic, and cytogenetic characteristics. Moreover, regional and racial differences have been reported in their incidence and subtype compositions. Here, we reviewed the epidemiology of lymphomas and summarized the recent achievements in specific subtypes prevalent in Korean population, focusing on clinical studies conducted by the Consortium for Improving Survival of Lymphoma (CISL) of the Korean Society of Hematology Lymphoma Working Party (KSH-LWP).

show abstract

Section: Survival Changes Based On Time In Major Subtypesmentioning

confidence: 99%

Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial

Yoo

Lee²,

Suh

et al. 2018

Int J Hematol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Twenty-one institutions participated in this non-randomized, multicenter, prospective, open-label, phase II study in Korea [ 8 ]. This clinical trial was approved by the institutional review boards and ethics committees of each participating institution.…”

Section: Methodsmentioning

confidence: 99%

Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study

Kim¹,

Kim²,

Kim³

et al. 2023

Cancer Res Treat

Self Cite

View full text Add to dashboard Cite

This phase II, open-label, multicenter study aimed to investigate the efficacy and safety of a rituximab intensification for the 1st cycle with every 21-day of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP-21) among patients with previously untreated advanced-stage or bulky diffuse large B-cell lymphoma (DLBCL). Materials and MethodsNinety-two patients with stage III/IV or bulky DLBCL from 21 institutions were administered 8 cycles of R-CHOP-21 with an additional one dose of rituximab intensification on day 0 of the 1st cycle (RR-CHOP). The primary endpoint was a complete response (CR) rate after 3 cycles of chemotherapy. ResultsAmong the 92 DLBCL patients assessed herein, the response rate after 3 cycles of chemotherapy was 88.0% (38.0% CR+50.0% partial response [PR]). After the completion of 8 cycles of chemotherapy, the overall response rate was observed for 68.4% (58.7% CR+9.8%

show abstract

The Consortium for Improving Survival of Lymphoma (CISL): recent achievements and future perspective

Cited by 2 publications

References 15 publications

Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial

Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial

Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study

Contact Info

Product

Resources

About